advancing innovation to save lives

GHTC fact sheet looks at role of R&D in advancing universal health coverage

GHTC released a new fact sheet examining how R&D of new drugs, vaccines, diagnostics, and other tools is a critical driver of universal health coverage. The resource looks at out how new and improved technologies can help expand access to care in low-resource communities, fill urgent treatment and prevention gaps to improve quality of care, overcome barriers to care among vulnerable populations, and generate health care system cost savings.
View

GHTC unveils new report on global health innovation at USAID

GHTC unveiled a new report examing how the US Agency for International Development’s (USAID) investments in global health innovation are an essential enabler in accelerating partner countries along the journey to self-reliance. It explores challenges and opportunities the agency faces in advancing this work and provides actionable recommendations for the administration and Congress to maximize the agency's health research and development activities.
View

Member Spotlight: Jhpiego

Jhpiego brings lifesaving care to those who need it the most. Together with governments and private partners, Jhpiego transforms communities and countries, from reviving the smallest, newest life, to attacking the most pressing health problems the world has ever faced.

Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 30 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more

PATH/Wendy Stone
GHTC Director quoted in The Verge on product development for emerging and infectious diseases

The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.

View

PATH
US FDA Approves New TB Drug in Treatment to Cure Practically Incurable XDR-TB

Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.

Learn More
View All News & Events

Community Event

Flickr/versello
74th United Nations General Assembly
United Nations
Learn More

Community Event

PATH/Gabe Bienczycki
United Nations High-Level Meeting on Universal Health Coverage
United Nations
Learn More
View All Events
PATH/Matthew Dakin
Research Roundup: The first chlamydia vaccine passed a major test, a new drug approved for drug-resistant tuberculosis, and two new Ebola treatments prove highly effective in the DRC

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Satvir Malhotra
Research Roundup: A portable “cholera detection lab," Sabin acquires rights to develop Ebola and Marburg vaccines, and Uganda starts largest-ever Ebola vaccine trial

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
View Breakthroughs Blog

Our members work to improve health worldwide